latest news on glp 1 drugs GLP-1s like Ozempic are among the most important drug breakthroughs ever Eli Lilly to seek approval
Description
What can be said is that the triple-agonist mechanism appears to produce a steeper dose-response curve than either the dual-agonist (tirzepatide) or single-agonist (semaglutide) approach
None of this stacks with NovoCare, so pick one path
Fetissov et al., 2002
PubMed 35
Based on hazard ratios, this equates to roughly a 58% increased risk of developing all thyroid cancers and a 78% increased risk of developing medullary thyroid cancer compared to controls
